- Home
- REBN vs ATHA Comparison
REBN vs ATHA Comparison
Compare REBN & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- ATHA
- Stock Information
- Founded
- REBN 2015
- ATHA 2011
- Country
- REBN United States
- ATHA United States
- Employees
- REBN N/A
- ATHA N/A
- Industry
- REBN Restaurants
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- REBN Consumer Discretionary
- ATHA Health Care
- Exchange
- REBN Nasdaq
- ATHA Nasdaq
- Market Cap
- REBN 15.3M
- ATHA 14.8M
- IPO Year
- REBN 2022
- ATHA 2020
- Fundamental
- Price
- REBN $2.45
- ATHA $0.39
- Analyst Decision
- REBN
- ATHA Hold
- Analyst Count
- REBN 0
- ATHA 3
- Target Price
- REBN N/A
- ATHA $0.50
- AVG Volume (30 Days)
- REBN 93.6K
- ATHA 103.2K
- Earning Date
- REBN 08-14-2025
- ATHA 08-07-2025
- Dividend Yield
- REBN N/A
- ATHA N/A
- EPS Growth
- REBN N/A
- ATHA N/A
- EPS
- REBN N/A
- ATHA N/A
- Revenue
- REBN $6,565,623.00
- ATHA N/A
- Revenue This Year
- REBN $335.98
- ATHA N/A
- Revenue Next Year
- REBN N/A
- ATHA N/A
- P/E Ratio
- REBN N/A
- ATHA N/A
- Revenue Growth
- REBN 14.03
- ATHA N/A
- 52 Week Low
- REBN $1.03
- ATHA $0.22
- 52 Week High
- REBN $8.30
- ATHA $3.03
- Technical
- Relative Strength Index (RSI)
- REBN 34.79
- ATHA 47.96
- Support Level
- REBN $2.91
- ATHA $0.38
- Resistance Level
- REBN $3.24
- ATHA $0.39
- Average True Range (ATR)
- REBN 0.19
- ATHA 0.02
- MACD
- REBN -0.06
- ATHA -0.00
- Stochastic Oscillator
- REBN 10.91
- ATHA 38.10
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.